You are here

  • Home
  • Archive
  • Volume 11, Issue 9
  • Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)

 

Online download statistics by month:

Online download statistics by month: September 2023 to March 2026

AbstractFullPdf
Sep 202313041308396
Oct 2023733737257
Nov 2023526530179
Dec 2023230234143
Jan 2024181184144
Feb 2024221223160
Mar 2024222223149
Apr 2024211211119
May 2024168171118
Jun 2024158162174
Jul 2024188188123
Aug 2024222221209
Sep 2024197198122
Oct 2024428428114
Nov 2024317318100
Dec 2024245247105
Jan 202521721888
Feb 202542642794
Mar 2025237237128
Apr 202519919994
May 2025197199130
Jun 2025939460
Jul 2025110
Sep 2025110
Mar 2026110
Total692369603206